Patents for A61P 35 - Antineoplastic agents (221,099)
01/2010
01/14/2010WO2010003992A1 Combination of a c-met antagonist and an aminoheteroaryl compound for the treatment of cancer
01/14/2010WO2010003805A1 Novel therapeutic use of a pharmaceutical composition for the reduction of the number of aberrant crypt foci and for the prevention of colon cancer
01/14/2010WO2010003700A1 9-alpha estratriene derivatives as er-beta selective ligands for the prevention and treatment of intestinal cancer
01/14/2010WO2010003668A2 Treatment of solid tumors with tissue inhibitors of metalloproteinases (timps)
01/14/2010WO2010003376A1 Methods for treatment and/or prevention of cancer with andrographolide (and) and use thereof
01/14/2010WO2010003369A1 Cyclin-dependent kinases inhibitor of baicalin organic amine derivatives, synthesis and use thereof
01/14/2010WO2010003313A1 Icotinib hydrochloride, synthesis, crystallographic form, medical combination, and uses thereof
01/14/2010WO2010003308A1 The use of nitric oxide and signal transduction system thereof in preparing medicaments for targeted therapy of malignant tumors
01/14/2010WO2010003279A2 A cryosurgery anticancer antigen preparation and its preparation method
01/14/2010WO2010003240A1 Gmcsf and truncated ccl2 conjugates and methods and uses thereof
01/14/2010WO2010003232A1 Treating cancer using atractyloside
01/14/2010WO2010003231A1 Multi-leu peptides and analogues thereof as selective pace4 inhibitors and effective antiproliferative agents
01/14/2010WO2010003193A1 Peptide inhibitors of cd40l signaling and uses therefor
01/14/2010WO2009143371A3 COMPOSITIONS COMPRISING mTOR SIRNA AND METHODS OF USE THEREOF
01/14/2010WO2009143167A3 Dual delivery system for heterologous antigens
01/14/2010WO2009142754A4 Dendritic conjugates and methods of use
01/14/2010WO2009141050A3 Linear self-eliminating oligomers
01/14/2010WO2009140754A8 An anti-cancer cytotoxic monoclonal antibody
01/14/2010WO2009138396A3 Conjugates for the treatment of mesothelioma
01/14/2010WO2009128917A3 Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
01/14/2010WO2009126551A3 Bis-aromatic anticancer agents
01/14/2010WO2009126335A3 Ant2 inhibitor compounds and methods of use thereof
01/14/2010WO2009124103A3 Combination therapies comprising par1 antagonists with par4 antagonists
01/14/2010WO2009108856A3 Microrna signatures associated with human chronic lymphocytic leukemia (ccl) and uses thereof
01/14/2010WO2009104100A3 Antibody combinations, and methods of making and using same
01/14/2010WO2009103969A8 Synthetic scfv analogue to the 6313/g2 (anti angiotensin ii type 1 receptor) monoclonal antibody variable regions
01/14/2010WO2009099650A4 Treatment of bladder diseases with a tlr7 activator
01/14/2010WO2009099465A3 Methods of using mir-199a as a marker and sequences of mir-199a as a therapeutic for cancer
01/14/2010WO2009098464A3 Use of g-rich oligonucleotides for treating neoplastic diseases
01/14/2010WO2009073139A3 Combined treatment with an egfr kinase inhibitor and an inhibitor of c-kit
01/14/2010WO2009052090A3 Silicate containing compositions and methods of treatment
01/14/2010WO2008133709A3 Targeted split biomolecular conjugates for the treatment of diseases, malignancies and disorders, and methods of their production
01/14/2010WO2008083312A3 Chemical linkers and cleavable substrates and conjugates thereof
01/14/2010US20100010207 Rna interference mediating small rna molecules
01/14/2010US20100010193 Immunogenic complexes and methods relating thereto
01/14/2010US20100010099 Medium and device for proliferation of stem cells and treatment of cancer-related stem cell with resveratrol
01/14/2010US20100010094 Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents
01/14/2010US20100010084 High penetration prodrug compositions of retinoids and retinoid-related compounds
01/14/2010US20100010083 Pharmaceutical composition for oral administration
01/14/2010US20100010081 Anti-tumor effect of dimeric phthalide compound
01/14/2010US20100010078 Methods of treating androgen dependent prostate cancer by administering an active pharmaceutical ingredient being fisetin, 3,3',4',7-tetrahydroxyflavone or a derivative thereof, in an oral, transdermal or topical dosage form
01/14/2010US20100010072 Microrna biomarkers for human breast and lung cancer
01/14/2010US20100010071 Compositions and use of EPAS1 inhibitors
01/14/2010US20100010064 Cancer treatment by combined inhibition of proteasome and telomerase activities
01/14/2010US20100010059 Anticancer oral formulation
01/14/2010US20100010057 Thiazole derivatives as inhibitors of p13 kinase
01/14/2010US20100010053 3-[7-(5-{3-Chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1H-indol-3-yl]propanoic acid; multiple sclerosis, autoimmune diseases, chronic inflammatory disorders, asthma, inflammatory neuropathies, arthritis, transplantation, Crohn's disease, ulcerative colitis, lupus erythematosis, psoriasis
01/14/2010US20100010037 1h-pyrrolo[2,3-b]pyridine derivatives useful as hsp90 inhibitors
01/14/2010US20100010033 Bis-carbazole DNA intercalating agents for antitumor therapy
01/14/2010US20100010032 Camptothecin derivatives with antitumor activity
01/14/2010US20100010023 Quinazoline derivatives and pharmaceutical compositions containing them
01/14/2010US20100010022 Use of pazopanib HCl and lapatinib
01/14/2010US20100010016 Bicyclic compounds having antimitotic and/or antitumor activity and methods of use thereof
01/14/2010US20100010014 Aminopyrimidine compounds and methods of use
01/14/2010US20100010010 Hdac inhibitors
01/14/2010US20100010008 Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
01/14/2010US20100010004 Inhibitors of histone deacetylase
01/14/2010US20100010002 Anticancer use of caffeic acid and its derivatives
01/14/2010US20100009998 Compositions and Methods Employing Aminopterin
01/14/2010US20100009992 Ampk modulators
01/14/2010US20100009988 Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase
01/14/2010US20100009982 Modulators of Acetyl-Coenzyme A Carboxylase and Methods of Use Thereof
01/14/2010US20100009978 Benzoxazoles and Oxazolopyridines Being Useful as Janus Kinases Inhibitors
01/14/2010US20100009963 Kinase antagonists
01/14/2010US20100009958 Quinazoline derivatives
01/14/2010US20100009949 Novel method
01/14/2010US20100009945 3,2-dihydrofuran-1 alpha ,25-dihydroxy-19-nor-vitamin D3; prophylaxis of autoimmune diseases, some types of cancers, metabolic bone diseases, osteomalacia, osteopenia, secondary hyperparathyroidism, psoriasis, or other skin diseases; osteoporosis
01/14/2010US20100009944 19-Nor-Vitamin D Analogs with 1,2-Dihydrofuran Ring
01/14/2010US20100009943 2-Methylene-(22E)-25-(1-Methylene-Hexyl)-26,27-Cyclo-22-Dehydro-19-Nor-Vitamin D Analogs
01/14/2010US20100009940 2-Methylene-(20E)-20(22)-Dehydro-19-Nor-Vitamin D Analogs
01/14/2010US20100009929 Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
01/14/2010US20100009928 Compositions including triciribine and taxanes and methods of use thereof
01/14/2010US20100009926 Ph-sensitive polymeric micelles for drug delivery
01/14/2010US20100009920 Ttk as tumor marker and therapeutic target for lung cancer
01/14/2010US20100009918 Method for the administration of ligands, agonists of ligands of the tnf family with reduced toxicity
01/14/2010US20100009915 Compositions comprising fungal immunomodulatory protein and use thereof
01/14/2010US20100009909 Peptides binding the phosphatase 2a protein
01/14/2010US20100009906 Anticancer Treatments
01/14/2010US20100009895 Method for selective localization of active agents at and in mitochondria and corresponding active agents
01/14/2010US20100009439 ANTI-IGF-I RECEPTOR ANTIBODIES, DNAs, VECTORS, HOST CELLS AND GENETIC CONSTRUCTS
01/14/2010US20100009435 SPECIFIC GRP78 EXPRESSION-INHIBITION RNAi SEQUENCE, MEDICINE THEREOF AND METHOD THEREOF
01/14/2010US20100009019 Processes for Extracting Phytochemicals from Pomegranate Solids and Compositions and Methods of Use Thereof
01/14/2010US20100009017 Anticancer Methods Using Extracts of Anemarrhena asphodeloides Bunge
01/14/2010US20100009000 Granule and preparation method thereof
01/14/2010US20100008998 Submicron nanoparticle of poorly water soluble camptothecin derivatives and process for preparation thereof
01/14/2010US20100008982 Non-covalent complexes of bioactive agents with starch for oral delivery
01/14/2010US20100008978 Nanoparticles effective for internalization into cells
01/14/2010US20100008975 Predicting response to a HER inhibitor
01/14/2010US20100008971 Chewing composition comprising coenzyme q10
01/14/2010US20100008966 Medical Devices and Methods for Delivery of Nucleic Acids
01/14/2010US20100008964 Isolated stromal cells and methods of using the same
01/14/2010US20100008953 Process for producing poxviruses and poxvirus compositions
01/14/2010US20100008946 Microorganisms for therapy
01/14/2010US20100008935 Method for identifying therapeutical targets in tumors, the use thereof and means for determining and targeting angiogenesis and hemostasis related to andenocarcinomas of the lung
01/14/2010US20100008931 Coronin 1 Modulators for the Treatment of Autoimmune and Lymphoproliferative Disorders and Mycobacterial Infections
01/14/2010US20100008929 Human monoclonal antibodies to epidermal growth factor receptor (egfr)
01/14/2010US20100008926 Novel proteins and use thereof
01/14/2010US20100008923 Organic Compounds
01/14/2010US20100008919 Peptide facilitating the entry of a linked molecule into a mammalian cancer cell; Using copper binding protein as a delivery vehicle; used to inhibit angiogenesis that accompanies tumor development
01/14/2010US20100008906 Cripto binding molecules